[1]刘卫东,刘建平,郭猛,等.胸部肿瘤适形和调强常规分割放疗脊髓生物效应剂量研究[J].国际放射医学核医学杂志,2018,(6):518-523.[doi:10.3760/cma.j.issn.1673-4114.2018.06.008]
　Liu Weidong,Liu Jianping,Guo Meng,et al.The study for biological effect dose of spinal cord in thoracic tumors with the model of conformal and intensity modulated technique and conventional fractionation[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(6):518-523.[doi:10.3760/cma.j.issn.1673-4114.2018.06.008]
点击复制

胸部肿瘤适形和调强常规分割放疗脊髓生物效应剂量研究(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
期数:
2018年第6期
页码:
518-523
栏目:
临床研究
出版日期:
2018-12-31

文章信息/Info

Title:
The study for biological effect dose of spinal cord in thoracic tumors with the model of conformal and intensity modulated technique and conventional fractionation
作者:
刘卫东1;  刘建平1;  郭猛2;  杨海芳1;  姜斌1;  徐春雨1
1. 063001, 唐山市人民医院放化科;
2. 518036, 深圳市医诺智能科技发展有限公司
Author(s):
Liu Weidong1;  Liu Jianping1;  Guo Meng2;  Yang Haifang1;  Jiang Bin1;  Xu Chunyu1
1. Department of Radio-chemotherapy, Tangshan People’s Hospital, Tangshan 063001, China;
2. Shenzhen Yino Intelligence Technology Co. Ltd, Shenzhen 518036, China
关键词:
胸部肿瘤; 放射疗法; 调强适形; 脊髓; 常规分割; 生物效应剂量
Keywords:
Thoracic neoplasms; Radiotherapy;  intensity-modulated; Spinal cord; Conventional fractionation; Biological effect dose
DOI:
10.3760/cma.j.issn.1673-4114.2018.06.008
摘要:
目的 探讨对常规分割模式下胸部肿瘤适形和调强放疗技术进行脊髓生物效应剂量（BED）评估的必要性和可行性。方法 选取2016年5月16日至2016年12月31日于唐山市人民医院放化疗科收治的胸部肿瘤患者30例，应用医诺RTIS治疗计划评估模块对所有患者的治疗计划进行评估，并进行物理剂量（PhD）和BED的比较。依据线性二次方程（L-Q模型）计算2.0 Gy照射1次和30次时脊髓在不同剂量曲线的PhD和RED。组间比较采用t检验。结果 脊髓的RED曲线位于PhD曲线左侧，计划靶体积（PTV）的BED曲线位于PhD曲线右侧。30例患者的治疗计划中，脊髓的最小、最大、平均PhD与BED分别为（80.41±274.75）、（3398.00±1200.95）、（1265.79±762.49）cGy和（74.71±249.34）、（3118.93±1181.96）、（1181.44±742.18）cGy，差异均有统计学意义（t=0.826、6.143、5.234，P<0.05）；PTV的最小、最大、平均PhD和BED分别为（3615.51±1566.10）、（5505.26±1731.64）、（4984.33±1615.59）cGy和（3500.97±1576.92）、（5672.93±1791.98）、（5047.63±1646.57）cGy，差异均无统计学意义（t=6.953、-2.164、-1.193，均P>0.05）。随着剂量曲线的下降，PhD和BED也随之降低，而且相应剂量曲线的BED较PhD更低。结论 从增强靶区控制和脊髓保护的角度，胸部肿瘤精确常规分割放疗有必要进行脊髓的BED评估。
Abstract:
Objective To investigate the necessity and feasibility of evaluation for spinal cord biological effect dose (BED) in clinical radiotherapy on thoracic tumors in the model of conformal or intensity modulated technique and conventional fractionation. Methods From 16 May 2016 to 31 December 2016, 30 patients accepting thoracic radiotherapy were selected in the Radio-chemotherapy department of Tangshan City People’s Hospital. Radiotherapy plans of these patients were evaluated by the evaluation module of the RTIS treatment plan system, and then the physical dose(PhD) and BED were compared, respectively. After that, the PhD and BED of the spinal cord in different dose curves for 2.0 Gy irradiation 1 and 30 times were calculated by the linear quadratic equation(L-Q model). T test was used for all comparison between groups in statistics. Results The BED curve of the spinal cord was on the left of the PhD curve, and the BED curve of planning target volume(PTV) was on the right of the PhD curve. In the radiotherapy plans of the 30 patients, for the spinal cord, the minimum maximum, average doses of PhD and BED were (80.41±274.75), (3398.00±1200.95), (1265.79±762.49) cGy and (74.71±249.34), (3118.93±1181.96), (1181.44±742.18) cGy, separately, the differences of them were significantly(t=0.826, 6.143, 5.234, all P<0.05). However, for the PTV of target the minimum, maximum, average doses of PhD and BED were (3615.51±1566.10), (5505.26±1731.64), (4984.33±1615.59) cGy and (3500.97±1576.92), (5672.93±1791.98), (5047.63±1646.57) cGy, all of them were no significances in statistics (t=6.953,-2.164,-1.193,all P>0.05). With the decline of the dose curve, the PhD and BED were reducing, and the BED were lower than the PhD in the curve for corresponding dose. Conclusions In the radiotherapy of thoracic tumors, considering potential enhancement of local target control and better spinal cord protection, it is necessary to evaluate the BED of the spinal cord.

参考文献/References:

[1] Jones B, Dale RG, Deehan C, et al. The role of biologically effective dose(BED) in clinical oncology[J]. Clin Oncol(R Coll Radiol), 2001, 13(2):71-81. DOI:10.1053/clon.2001.9221.
[2] Fowler JF. 21 years of biologically effective dose[J]. Br J Radiol, 2010, 83(991):554-568. DOI:10.1259/bjr/31372149.
[3] Mouttet-Audouard R, Lacornerie T, Tresch E, et al. What is the normal tissues morbidity following Helical Intensity Modulated Radiation Treatment for cervical cancer?[J]. Radiother Oncol, 2015, 115(3):386-391. DOI:10.1016/j.radonc.2015.02.010.
[4] Hopewell JW, Millar WT, Lindquist C, et al. Application of the concept of biologically effective dose (BED) to patients with Vestibular Schwannomas treated by radiosurgery[J]. J Radiosurg SBRT, 2013, 2(4):257-271.
[5] Su SF, Huang Y, Xiao WW, et al. Clinical and dosimetric characteristics of temporal lobe injury following intensity modulated radiotherapy of nasopharyngeal carcinoma[J]. Radiother Oncol, 2012, 104(3):312-316. DOI:10.1016/j.radonc.2012.06.012.
[6] Lee SH, Lee KC, Choi J, et al. Clinical applicability of biologically effectivedose calculation for spinal cord in fractionatedspine stereotactic body radiation therapy[J]. Radiol Oncol, 2015, 49(2):185-191. DOI:10.1515/raon-2015-0008.
[7] Wambersie A, Menzel HG, Gahbauer RA, et al. Biological weighting of absorbed dose in radiation therapy[J]. Radiat Prot Dosimetry, 2002, 99(1/4):445-452.
[8] Iwata H, Matsufuji N, Toshito T, et al. Compatibility of the repairable-conditionally repairable, multi-target and linear-quadratic models in converting hypofractionated radiation doses to single doses[J]. J Radiat Res, 2013, 54(2):367-373. DOI:10.1093/jrr/rrs089.
[9] Jin JY, Huang YM, Brown SL, et al. Radiation dose-fractionation effects in spinal cord:comparison of animal and human data[J]. J Radiat Oncol, 2015, 4(3):225-233. DOI:10.1007/s13566-015-0212-9.
[10] Deloch L, Derer A, Hartmann J, et al. Modern Radiotherapy Concepts and the Impact of Radiation on Immune Activation[J]. Front Oncol, 2016, 6:141. DOI:10.3389/fonc.2016.00141.
[11] 李玉, 徐慧军. 现代肿瘤放射物理学[M]. 北京:中国原子能出版社, 2015:526-530. Li Y, Xu HJ. Modern radiophysicson tumor[M]. Beijing:China Atomic Energy Press, 2015:526-530.
[12] Gandhi AK, Sharma DN, Rath GK, et al. Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma:a prospective randomized study[J]. Int J Radiat Oncol Biol Phys, 2013, 87(3):542-548. DOI:10.1016/j.ijrobp.2013.06.2059.
[13] Co J, Mejia MB, Dizon JM. Evidence on effectiveness of intensity-modulated radiotherapy versus 2-dimensional radiotherapy in the treatment of nasopharyngeal carcinoma:Meta-analysis and a systematic review of the literature[J]. Head Neck, 2016, 38 Suppl 1:E2130S-2142. DOI:10.1002/hed.23977.
[14] Peng G, Wang T, Yang KY, et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma[J]. Radiother Oncol, 2012, 104(3):286-293. DOI:10.1016/j.radonc.2012.08.013.
[15] Zhang MX, Li J, Shen GP, et al. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy:A 10-year experience with a large cohort and long follow-up[J]. Eur J Cancer, 2015, 51(17):2587-2595. DOI:10.1016/j.ejca. 2015.08.006.
[16] Zhou GQ, Yu XL, Chen M, et al. Radiation-induced temporal lobe injury for nasopharyngeal carcinoma:a comparison of intensity-modulated radiotherapy and conventional two-dimensional radiotherapy[J/OL]. PLoS One, 2013, 8(7):e67488[2018-02-05]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3707870/pdf/pone.0067488.pdf. DOI:10.1371/journal.pone.0067488.
[17] Dolezel M, Odrazka K, Zouhar M, et al. Comparing morbidity and cancer control after 3D-conformal (70/74 Gy) and intensity modulated radiotherapy (78/82 Gy) for prostate cancer[J]. Strahlenther Onkol, 2015, 191(4):338-346. DOI:10.1007/s00066-014-0806-y.
[18] 殷蔚伯, 余子豪, 徐国镇, 等. 肿瘤放射治疗学[M]. 4版. 北京:中国协和医科大学出版社, 2008:276. Yin WB, Yu ZH, Xu GZ, et al. Radiation oncology[M]. 4th ed. Beijing:China Union Medical University Press, 2008:276.
[19] Chadwick HK, Leenhouts HP. A molecular therapy of cell survival[J]. Physic Med Biol, 1973, 18:78-87.
[20] Sanpaolo P, Barbieri V, Genovesi D. Biologically effective dose and definitive radiation treatment for localized prostate cancer:treatment gaps do affect the risk of biochemical failure[J]. Strahlenther Onkol, 2014, 190(8):732-738. DOI:10.1007/s00066-014-0642-0.
[21] Jin JY, Huang Y, Brown SL, et al. Radiation dose-fractionation effects in spinal cord:comparison of animal and human data[J]. J Radiat Oncol, 2015, 4(3):225-233. DOI:10.1007/s13566-015-0212-9.
[22] Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses[J]. Int J Radiat Oncol Biol Phys, 1982, 8(11):1981-1997.
[23] Maciejewski B, Taylor JM, Withers HR. Alpha/beta value and the importance of size of dose per fraction for late complications in the supraglottic larynx[J]. Radiother Oncol, 1986, 7(4):323-326.
[24] Brenner DJ. Fractionation and late rectal toxicity[J]. Int J Radiat Oncol Biol Phys, 2004, 60(4):1013-1015. DOI:10.1016/j.ijrobp.2004.04.014.
[25] Miralbell R, Robert SA, Zubizarreta E, et al. Dose-fraction sensitivity of prostate cancer deduced from radiotherapy outcomes of 5969 patients in seven international institutional datasets:α/β=1.4(0.9-2.2) Gy[J]. Int J Radiat Oncol Biol Phys, 2012, 82(1):e17-24. DOI:10.1016/j.ijrobp.2010.10.075.
[26] Turesson I, Notter G. The influence of fraction size in radiotherapy on the late normal tissue reaction -I:Comparison of the effects of daily and once-a-week fractionation on human skin[J]. Int J Radiat Oncol Biol Phys, 1984, 10(5):593-598.
[27] Machtay M, Bae K, Movsas B, et al. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation:an analysis of the radiation therapy oncology group[J]. Int J Radiat Oncol Biol Phys, 2012, 82(1):425-434. DOI:10.1016/j.ijrobp.2010.09.004.
[28] Xia B, Chen GY, Cai XW, et al. The effect of bioequivalent radiation dose on survival of patients with limited-stage small-cell lung cancer[J]. Radiat Oncol, 2011, 6:50. DOI:10.1186/1748-717X-6-50.

相似文献/References:

[1]李景涛,邓垒,张文珏,等.广泛期小细胞肺癌胸部IMRT后发生放射性肺炎的危险因素分析[J].国际放射医学核医学杂志,2016,40(2):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
　Li Jingtao,Deng Lei,Zhang Wenjue,et al.Risk factor analysis for predicting radiation pneumonitis in extensive stage small cell lung cancer patients receiving IMRT thoracic radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
[2]刘佳,高刚,朴春南,等.调节肿瘤放射敏感性的miRNAs研究进展[J].国际放射医学核医学杂志,2016,40(2):159.[doi:10.3760/cma.j.issn.1673-4114.2016.02.015]
　Liu Jia,Gao Gang,Piao Chunnan,et al.Progress of microRNAs in regulating tumor radiation sensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):159.[doi:10.3760/cma.j.issn.1673-4114.2016.02.015]
[3]陈晓艳,张江虹,邵春林.STAT3与辐射敏感相关性的研究进展[J].国际放射医学核医学杂志,2016,40(3):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
　Chen Xiaoyan,Jianghong,Shao Chunlin.Research progresses of correlation between STAT3 and radiosensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
[4]赵德云,李百龙.植物提取物防治放射性肺损伤的现状与展望[J].国际放射医学核医学杂志,2016,40(3):208.[doi:10.3760/cma.j.issn.1673-4114.2016.03.010]
　Zhao Deyun,Li Bailong.Protective and therapeutic effects of plant extracts on radiation-induced lung injury:present status and future prospects[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):208.[doi:10.3760/cma.j.issn.1673-4114.2016.03.010]
[5]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[6]邓大平,卢峰,孙洪强,等.颅脑肿瘤放射治疗时射野外器官吸收剂量体模法测量与分析[J].国际放射医学核医学杂志,2016,40(4):272.[doi:10.3760/cma.j.issn.1673-4114.2016.04.007]
　Deng Daping,Lu Feng,Sun Hongqiang,et al.Test and analysis of out-of-field organ dose in intracranial tumor radiotherapy using phantom[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):272.[doi:10.3760/cma.j.issn.1673-4114.2016.04.007]
[7]赵舒怡,储小飞,樊赛军.血清肿瘤标志物与肿瘤放疗疗效评估的研究进展[J].国际放射医学核医学杂志,2015,39(5):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
　zhao shuyi,chu xiaofei,fan saijun..progression of study on serum tumor markers in evaluation of tumor radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
[8]赵徵鑫,翟贺争,张文艺,等.质子重离子治疗肿瘤的进展[J].国际放射医学核医学杂志,2016,40(5):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
　Zhao Zhixin,Zhai Hezheng,Zhang Wenyi,et al.Development of proton heavy ion in tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
[9]段永璇,邹晓艳,段秀梅,等.数据解析在肿瘤放射治疗中的应用[J].国际放射医学核医学杂志,2015,39(6):505.[doi:10.3760/cma.j.issn.1673-4114.2015.06.015]
　Duan Yongxuan,Zou Xiaoyan,Duan Xiumei,et al.Data analysis in the field of tumor radiation therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):505.[doi:10.3760/cma.j.issn.1673-4114.2015.06.015]
[10]贾立立,孟粹达,刘晓冬,等.头颈部肿瘤放疗中转化医学相关机制的研究进展[J].国际放射医学核医学杂志,2015,39(3):247.[doi:10.3760/cma.j.issn.1673-4114.2015.03.013]
　Jia Lili,Meng Cuida,Liu Xiaodong,et al.Development in translational medicine-related mechanisms of radiotherapy for head and neck cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):247.[doi:10.3760/cma.j.issn.1673-4114.2015.03.013]
[11]翟小明,王建平,张军,等.放射性肺炎CT灌注成像的临床研究[J].国际放射医学核医学杂志,2008,32(5):314.
　ZHAI Xiao-ming,WANG Jian-ping,ZHANG Jun-ning,et al.Application of CT perfusion imaging in radiation pneumonitis[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(6):314.

备注/Memo

备注/Memo:
收稿日期:2018-02-07。
通讯作者:刘卫东,Email:13333299761@189.cn
更新日期/Last Update: 2018-12-31